Endpoints and Assessments The primary study objective was to confirm bioequivalence of the two oral formulations of semaglutide (2G vs 1G) administered once daily at three dose levels at SS in healthy participants, namely 2G oral semaglutide 1.5 mg versus 1G oral semaglutide 3 mg, 2G oral semaglutide 4 mg versus 1G oral semaglutide 7 mg, and 2G oral semaglutide 9 mg versus 1G oral semaglutide 14 mg
Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg inpatients with type 2diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
In clinical studies, participants lost an average of 15% to 20% of their body weight over time
Genetic insights also help explain why your neighbor's results on semaglutide differ from yoursbiology, not willpower, drives much of the variation in weight loss outcomes
In subsequent publications, we will more deeply examine and present the definitions of SMM and strength and function, methodological gaps, and research needed to bring robust evidence to the topic
The art of tissue-specific and disease-specific dosing may emerge in the not-too-distant future: Rather than using the current pharmacologic doses of GLP-1s to soak receptors throughout the body, we may learn how to apply much more tailored brush strokes to effectively treat, say, dementia or rheumatoid arthritis